Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L. P. is pleased to announce that Dan O’Korn, former Vice President of Legal Affairs and Business Development for Xcellerex, Inc., recently joined the Firm as Counsel.
Mr. O’Korn brings to Smith Anderson the experience gained as both a private practicing attorney and in house counsel for pharmaceutical and biotech companies, including serving as General Counsel. Along with his work with Xcellerex, Mr. O’Korn is a former partner with Hunton & Williams and served as in house counsel for Eli Lilly and Company, AAIPharma, Inc. and Xanodyne Pharmaceuticals, Inc.
Mr. O’Korn’s practice is focused on business transactions within the pharmaceutical and biotech industries, including licensing and development transactions, asset acquisitions and divestitures, co-promotion and co-marketing agreements, and commercial supply transactions.
“We are thrilled that Dan has joined our Firm,” said John Jernigan, Smith Anderson’s Managing Partner. “Adding Dan’s experience in the pharmaceutical and biotech industries will strengthen our existing practices, and provide tremendous value to our clients.”